Daxdilimab is under clinical development by Horizon Therapeutics and currently in Phase II for Alopecia Areata. According to GlobalData, Phase II drugs for Alopecia Areata does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Daxdilimab LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Daxdilimab (VIB-7734, MEDI-7734) is under development for the treatment of type I interferon-mediated autoimmune diseases including systemic lupus erythematosus, cutaneous lupus erythematosus, dermatomyositis, anti-synthetase inflammatory myositis, lupus nephritis and alopecia areata. It is administered through intravenous and subcutaneous route. It is a monoclonal antibody that binds to an extracellular domain of human ILT7. The drug candidate is developed based on dendritic cell platform.
It was also under development for COVID-19-related pneumonia and acute lung injury and polymyositis, Sjogren's syndrome, systemic sclerosis.
For a complete picture of Daxdilimab’s drug-specific PTSR and LoA scores, buy the report here.